Last reviewed · How we verify
Cefazoline
At a glance
| Generic name | Cefazoline |
|---|---|
| Sponsor | Nantes University Hospital |
| Target | Bacterial penicillin-binding protein, Penicillin-binding protein 1A |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Bacterial endocarditis
- Bacterial pneumonia
- Bacterial septicemia
- Bacterial urinary infection
- Cholangitis
- Genitourinary Tract Infections
- Infection of biliary tract
- Infection of bone
- Infection of skin AND/OR subcutaneous tissue
- Infectious disorder of joint
- Lower respiratory tract infection
- Pneumonia due to Streptococcus
- Prevention of Perioperative Infection
- Staphylococcal pneumonia
Common side effects
Key clinical trials
- Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (PHASE4)
- IO Vancomycin Spine (PHASE2, PHASE3)
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- Antibiotics for Prevention of Infection Following Orthognathic Surgery (PHASE4)
- Prophylaxis Against Surgical Site Infections Using Local as Well as Systemic Antibiotic (NA)
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial (PHASE4)
- Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefazoline CI brief — competitive landscape report
- Cefazoline updates RSS · CI watch RSS
- Nantes University Hospital portfolio CI